13.31
price up icon1.83%   0.205
 
loading

Urogen Pharma Ltd Borsa (URGN) Ultime notizie

pulisher
Jun 19, 2025

Urogen Pharma (NASDAQ:URGN) Short Interest Down 29.9% in May - Defense World

Jun 19, 2025
pulisher
Jun 19, 2025

HC Wainwright Decreases Earnings Estimates for Urogen Pharma - Defense World

Jun 19, 2025
pulisher
Jun 18, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd.URGN - FinancialContent

Jun 18, 2025
pulisher
Jun 18, 2025

UroGen Pharma Ltd (NASDAQ: URGN) Stock: A Value Hunter’s Investment? - Stocksregister

Jun 18, 2025
pulisher
Jun 17, 2025

H.C. Wainwright Sees Billion Dollar Potential in UroGen’s New Therapy - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

UroGen Pharma (NASDAQ:URGN) Sees Large Volume Increase Following Analyst Upgrade - Defense World

Jun 17, 2025
pulisher
Jun 17, 2025

UroGen Pharma (NASDAQ:URGN) Upgraded to “Buy” at HC Wainwright - Defense World

Jun 17, 2025
pulisher
Jun 16, 2025

UROGEN PHARMA LTD. (NASDAQ: URGN) SHAREHOLDER ALERT - GlobeNewswire

Jun 16, 2025
pulisher
Jun 16, 2025

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Reckitt, UroGen and Fortrea and Encourages Investors to Contact the Firm - GlobeNewswire Inc.

Jun 16, 2025
pulisher
Jun 16, 2025

UroGen Investor Drops Cancer Drug Suit Following FDA Approval - Bloomberg Law News

Jun 16, 2025
pulisher
Jun 16, 2025

Investors who lost money on UroGen Pharma Ltd.(URGN) should contact Levi & Korsinsky about ... - Eagle-Tribune

Jun 16, 2025
pulisher
Jun 16, 2025

Investors who lost money on UroGen Pharma Ltd.(URGN) should - GlobeNewswire

Jun 16, 2025
pulisher
Jun 16, 2025

URGN SHAREHOLDER REPORT: UroGen Pharma Ltd. was Sued for - GlobeNewswire

Jun 16, 2025
pulisher
Jun 16, 2025

Lost Money on UroGen Pharma Ltd. (URGN)? Contact Levi & Korsinsky Before July 28, 2025 to Join Class Action - ACCESS Newswire

Jun 16, 2025
pulisher
Jun 16, 2025

URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire

Jun 16, 2025
pulisher
Jun 16, 2025

HC Wainwright Upgrades UroGen Pharma to Buy From Neutral, $50 Price Target - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

UroGen Pharma Ltd. Class Action: The Gross Law Firm Reminds UroGen Pharma Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 28, 2025URGN - PR Newswire

Jun 16, 2025
pulisher
Jun 15, 2025

Lost Money on UroGen Pharma Ltd. (URGN)? Urged to Join Class Action Before July 28, 2025Contact Levi & Korsinsky - ACCESS Newswire

Jun 15, 2025
pulisher
Jun 15, 2025

URGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that UroGen Pharma Ltd. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Jun 15, 2025
pulisher
Jun 15, 2025

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - GlobeNewswire Inc.

Jun 15, 2025
pulisher
Jun 15, 2025

Scotiabank Raises UroGen Pharma (NASDAQ:URGN) Price Target to $47.00 - Defense World

Jun 15, 2025
pulisher
Jun 15, 2025

UroGen Pharma (NASDAQ:URGN) Stock Price Expected to Rise, Guggenheim Analyst Says - Defense World

Jun 15, 2025
pulisher
Jun 14, 2025

UroGen Pharma (NASDAQ:URGN) Shares Gap Up After Analyst Upgrade - Defense World

Jun 14, 2025
pulisher
Jun 13, 2025

URGN INVESTOR NOTICE: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - Kilgore News Herald

Jun 13, 2025
pulisher
Jun 13, 2025

UroGen Pharma Ltd. (URGN) Faces Securities Class Action - GlobeNewswire

Jun 13, 2025
pulisher
Jun 13, 2025

URGN INVESTOR DEADLINE: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - The Victoria Advocate

Jun 13, 2025
pulisher
Jun 13, 2025

Goldman Sachs Increases Price Target for UroGen Pharma (URGN) Af - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

UroGen Pharma Gains Amid Analyst Ratings in Biopharma Sector Russell 1000 - Kalkine Media

Jun 13, 2025
pulisher
Jun 13, 2025

UroGen Pharma price target raised to $31 from $10 at Oppenheimer - Investing.com India

Jun 13, 2025
pulisher
Jun 13, 2025

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote - insights.citeline.com

Jun 13, 2025
pulisher
Jun 13, 2025

UroGen Pharma (URGN) Receives Price Target Boost to $31 After Zusduri Approval | URGN Stock News - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Why UroGen Pharma (URGN) Stock Is Skyrocketing This Week - Benzinga

Jun 13, 2025
pulisher
Jun 13, 2025

UroGen Pharma (URGN) Sees Price Target Doubled by Scotiabank | URGN Stock News - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff - GlobeNewswire

Jun 13, 2025
pulisher
Jun 13, 2025

UroGen Pharma: Lessons Learned And Future Outlook (NASDAQ:URGN) - Seeking Alpha

Jun 13, 2025
pulisher
Jun 13, 2025

Scotiabank Boosts UroGen Pharma (URGN) Price Target Amid FDA Opt - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Zusduri flurry ends; ‘set up’ at ODAC, Urogen prevails with FDA - BioWorld MedTech

Jun 13, 2025
pulisher
Jun 13, 2025

UroGen Pharma (URGN) Soars After FDA Approval and Price Target B - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Why Is UroGen Pharma Stock Trading Higher On Friday?UroGen Pharma (NASDAQ:URGN) - Benzinga

Jun 13, 2025
pulisher
Jun 13, 2025

Scotiabank Boosts UroGen Pharma (URGN) Price Target Amid FDA Optimism | URGN Stock News - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

UroGen Pharma (URGN) Stock Outlook: Guggenheim Raises Price Target | URGN Stock News - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

URGN Investors Have the Opportunity to Lead the UroGen Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - StreetInsider

Jun 13, 2025
pulisher
Jun 13, 2025

UroGen Soars On Price Target Upgrade On Heels Of FDA Approval For Cancer Medicine: Retail Sees Stock Touching $20 - Asianet Newsable

Jun 13, 2025
pulisher
Jun 13, 2025

UroGen continues to climb after bladder cancer drug approval - Seeking Alpha

Jun 13, 2025
pulisher
Jun 13, 2025

Transcript : UroGen Pharma Ltd.Special Call - marketscreener.com

Jun 13, 2025
pulisher
Jun 13, 2025

UroGen's Zusduri wins FDA's blessing as first therapy for certain bladder cancer patients, despite negative adcomm vote - Fierce Pharma

Jun 13, 2025
pulisher
Jun 13, 2025

UroGen Pharma (NASDAQ:URGN) Given “Buy” Rating at D. Boral Capital - Defense World

Jun 13, 2025
pulisher
Jun 13, 2025

UroGen Pharma stock soars as FDA approves Zusduri despite negative panel vote - Investing.com India

Jun 13, 2025
pulisher
Jun 13, 2025

FDA approves UroGen Pharma’s bladder cancer treatment - Investing.com

Jun 13, 2025
pulisher
Jun 13, 2025

UroGen Pharma stock price target raised to $47 from $23 at Scotiabank - Investing.com

Jun 13, 2025
pulisher
Jun 13, 2025

Guggenheim Boosts UroGen Pharma (URGN) Price Target Following FDA Approval | URGN Stock News - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

FDA greenlights UroGen’s Zusduri for recurrent bladder cancer patients - The Pharma Letter

Jun 13, 2025
pulisher
Jun 13, 2025

UroGen Pharma Ltd. Sued for Securities Law ViolationsContact Levi & Korsinsky Before July 28, 2025 to Discuss Your RightsURGN - Morningstar

Jun 13, 2025
pulisher
Jun 13, 2025

The Gross Law Firm Notifies UroGen Pharma Ltd. Investors of a Class Action Lawsuit and Upcoming Deadline – URGN - GlobeNewswire

Jun 13, 2025
pulisher
Jun 12, 2025

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen - GlobeNewswire

Jun 12, 2025
pulisher
Jun 12, 2025

Health Care Climbs Amid Deal ActivityHealth Care Roundup - marketscreener.com

Jun 12, 2025
pulisher
Jun 12, 2025

URGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire

Jun 12, 2025
pulisher
Jun 12, 2025

UroGen soars 50% on FDA approval of historic bladder cancer treatment - Investing.com Australia

Jun 12, 2025
pulisher
Jun 12, 2025

UroGen Pharma (URGN) Gains After FDA Greenlights Zusduri | URGN Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

US FDA approves UroGen's bladder cancer drug - marketscreener.com

Jun 12, 2025
pulisher
Jun 12, 2025

Scotiabank Raises UroGen Pharma Price Target to $47 From $23, Maintains Sector Outperform Rating - marketscreener.com

Jun 12, 2025
pulisher
Jun 12, 2025

FDA okays UroGen's bladder cancer treatment after narrow ODAC rebuff - FirstWord Pharma

Jun 12, 2025
pulisher
Jun 12, 2025

FDA approves UroGen’s ZUSDURI for bladder cancer treatment - Investing.com Australia

Jun 12, 2025
pulisher
Jun 12, 2025

U.S. FDA Approves UroGen Pharma Ltd.'s ZUSDuri?? for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-NMIBC) - marketscreener.com

Jun 12, 2025
$20.42
price down icon 1.37%
$35.45
price up icon 0.65%
$21.06
price down icon 1.92%
$101.83
price down icon 0.41%
$105.86
price down icon 0.39%
biotechnology ONC
$244.00
price down icon 3.69%
Capitalizzazione:     |  Volume (24 ore):